Re: Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study: authors' response

被引：1
|
作者：
Shasha, David [1 ,2 ,3 ]
Heymann, Anthony D. [1 ,2 ]
Zacay, Galia [1 ,2 ]
机构：
[1] Meuhedet Hlth Maintenance Org, 124 Even Gevirol St, IL-6203854 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Infect Dis Unit, Tel Aviv, Israel
来源：
CLINICAL MICROBIOLOGY AND INFECTION | 2022年 / 28卷 / 03期
关键词：
D O I：
10.1016/j.cmi.2021.12.010
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：454 / 455
页数：2
相关论文
共 50 条
  • [1] Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study
    Shasha, David
    Bareket, Ronen
    Sikron, Fabienne Hershkowitz
    Gertel, Omer
    Tsamir, Judith
    Dvir, David
    Mossinson, David
    Heymann, Anthony D.
    Zacay, Galia
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (01) : 130 - 134
  • [2] Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study' by Shasha et al
    Scorza, Fulvio Alexandre
    Finsterer, Josef
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (03) : 452 - 453
  • [3] Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers
    Oliveira-Silva, Joana
    Reis, Teresa
    Lopes, Cristiana
    Batista-Silva, Ricardo
    Ribeiro, Ricardo
    Marques, Gilberto
    Pacheco, Vania
    Rodrigues, Tiago
    Afonso, Alexandre
    Pinheiro, Vitor
    Araujo, Lucilia
    Rodrigues, Fernando
    Antunes, Isabel
    [J]. VACCINE, 2022, 40 (04) : 650 - 655
  • [4] Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data
    Tene, Lilac
    Karasik, Avraham
    Chodick, Gabriel
    Pereira, Dora I. A.
    Schou, Henrik
    Waechter, Sandra
    Gohring, Udo-Michael
    Drakesmith, Hal
    [J]. PLOS ONE, 2023, 18 (05):
  • [5] BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study
    Zacay, Galia
    Shasha, David
    Bareket, Ronen
    Kadim, Itai
    Hershkowitz Sikron, Fabienne
    Tsamir, Judith
    Mossinson, David
    Heymann, Anthony D.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (06):
  • [6] SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
    Falsey, Ann R.
    Frenck, Robert W., Jr.
    Walsh, Edward E.
    Kitchin, Nicholas
    Absalon, Judith
    Gurtman, Alejandra
    Lockhart, Stephen
    Bailey, Ruth
    Swanson, Kena A.
    Xu, Xia
    Koury, Kenneth
    Kalina, Warren
    Cooper, David
    Zou, Jing
    Xie, Xuping
    Xia, Hongjie
    Tuereci, Ozlem
    Lagkadinou, Eleni
    Tompkins, Kristin R.
    Shi, Pei-Yong
    Jansen, Kathrin U.
    Sahin, Ugur
    Dormitzer, Philip R.
    Gruber, William C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (17): : 1627 - 1629
  • [7] BNT162b2 Vaccine against SARS-CoV-2 effective in Children
    Meinrenken, Susanne
    [J]. PNEUMOLOGIE, 2022, 76 (03):
  • [8] Skin reaction following SARS-CoV-2 vaccine BNT162b2
    Russo, Filomena
    Santi, Francesco
    Sirchio, Azzurra
    Lazzeri, Laura
    De Piano, Ernesto
    Taddeucci, Paolo
    Rubegni, Pietro
    [J]. ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2023, 158 (04) : 360 - 361
  • [9] Longitudinal study of antibody response following SARS-CoV-2 vaccination with Pfizer-BioNTech BNT162b2
    Navas, Leandra J. Robles
    Huete, Juan J. Ortega
    Sanchis, Maria L. Julia
    Miro, Jorge S. Bravo
    Sanchez, Serezade Cervera
    Gasset, Ricardo Molina
    [J]. ADVANCES IN LABORATORY MEDICINE-AVANCES EN MEDICINA DE LABORATORIO, 2023, 4 (03): : 298 - 302
  • [10] Longitudinal study of the antibody response after vaccination against SARS-CoV-2 with the BNT162b2 vaccine from Pfizer-BioNtech
    Navas, Leandra J. Robles
    Huete, Juan J. Ortega
    Sanchis, Maria L. Julia
    Miro, Jorge S. Bravo
    Sanchez, Serezade Cervera
    Gasset, Ricardo Molina
    [J]. ADVANCES IN LABORATORY MEDICINE-AVANCES EN MEDICINA DE LABORATORIO, 2023, 4 (03): : 303 - 307
12345